MCSTAP Case Discussion Series: Part 2: Buprenorphine in the Era of Fentanyl - June 20, 2024
This site is for learners who attended the live June 20, 2024, program to claim credit.
Claiming Credit
Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete the evaluation and claim your credit on the following page.
ADA statement: To request reasonable accommodations for a disability please contact MCSTAP@carelon.com, in writing, at least two weeks prior to the activity.
Target Audience
Primary care physicians, internists, family practice physicians, nurse practitioners, nurses, and physician assistants
Learning Objectives
- Learn the nuts and bolts of buprenorphine prescribing
- Become familiar with buprenorphine induction strategies and levels of evidence
- Explore the impact of illicitly manufactured fentanyl on buprenorphine dosing and newer buprenorphine formulations
- Review cases related to the impact of fentanyl on buprenorphine prescribing
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for 1 hour of opioid education.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 MA Opioid Education Statement
- 1.00 Participation